Gigantism caused by growth hormone secreting pituitary adenoma
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Gigantism indicates excessive secretion of growth hormones (GH) during childhood when open epiphyseal growth plates allow for excessive linear growth. Case one involved a 14.7-year-old boy presented with extreme tall stature. His random serum GH level was 38.4 ng/mL, and failure of GH suppression was noted during an oral glucose tolerance test (OGTT; nadir serum GH, 22.7 ng/mL). Magnetic resonance imaging (MRI) of the brain revealed a 12-mm-sized pituitary adenoma. Transsphenoidal surgery was performed and a pituitary adenoma displaying positive immunohistochemical staining for GH was reported. Pituitary MRI scan was performed 4 months after surgery and showed recurrence/residual tumor. Medical treatment with a long-acting somatostatin analogue for six months was unsuccessful. As a result, secondary surgery was performed. Three months after reoperation, the GH level was 0.2 ng/mL and insulin-like growth factor 1 was 205 ng/mL. Case two involved a 14.9-year-old boy, who was referred to our department for his tall stature. His basal GH level was 9.3 ng/mL, and failure of GH suppression was reported during OGTT (nadir GH, 9.0 ng/mL). Pituitary MRI showed a 6-mm- sized pituitary adenoma. Surgery was done and histopathological examination demonstrated a pituitary adenoma with positive staining for GH. Three months after surgery, the GH level was 0.2 ng/mL and nadir GH during OGTT was less than 0.1 ng/mL. Pituitary MRI scans showed no residual tumor. We present two cases of gigantism caused by a GH-secreting pituitary adenoma with clinical and microscopic findings.
Abstract
Gigantism indicates excessive secretion of growth hormones (GH) during childhood when open epiphyseal growth plates allow for excessive linear growth. Case one involved a 14.7-year-old boy presented with extreme tall stature. His random serum GH level was 38.4 ng/mL, and failure of GH suppression was noted during an oral glucose tolerance test (OGTT; nadir serum GH, 22.7 ng/mL). Magnetic resonance imaging (MRI) of the brain revealed a 12-mm-sized pituitary adenoma. Transsphenoidal surgery was performed and a pituitary adenoma displaying positive immunohistochemical staining for GH was reported. Pituitary MRI scan was performed 4 months after surgery and showed recurrence/residual tumor. Medical treatment with a long-acting somatostatin analogue for six months was unsuccessful. As a result, secondary surgery was performed. Three months after reoperation, the GH level was 0.2 ng/mL and insulin-like growth factor 1 was 205 ng/mL. Case two involved a 14.9-year-old boy, who was referred to our department for his tall stature. His basal GH level was 9.3 ng/mL, and failure of GH suppression was reported during OGTT (nadir GH, 9.0 ng/mL). Pituitary MRI showed a 6-mm- sized pituitary adenoma. Surgery was done and histopathological examination demonstrated a pituitary adenoma with positive staining for GH. Three months after surgery, the GH level was 0.2 ng/mL and nadir GH during OGTT was less than 0.1 ng/mL. Pituitary MRI scans showed no residual tumor. We present two cases of gigantism caused by a GH-secreting pituitary adenoma with clinical and microscopic findings.
참고문헌 (19)
- Eugster EA, "Gigantism", J Clin Endocrinol Metab, 84, pp.4379~4384 (1999)
- Whitehead EM, "Pituitary gigantism: a disabling condition", Clin Endocrinol, 17, pp.271~277 (1982)
- Kane LA, "Pituitary adenomas in childhood and adolescence", J Clin Endocrinol Metab, 79, pp.1135~1140 (1994)
- Artese R, "Pituitary tumors in adolescent patients", Neurol Res, 20, pp.415~417 (1998)
- Abe T, "Growth hormone-secreting pituitary adenomas in childhood and adolescence: features and results of transnasal surgery", Neurosurgery, 45, pp.1~10 (1999)
- Melmed S, "Clinical review 75: recent advances in pathogenesis, diagnosis, and management of acromegaly", J Clin Endocrinol Metab, 80, pp.3395~3402 (1995)
- Dyer EH, "Transsphenoidal surgery for pituitary adenomas in children", Neurosurgery, 34, pp.207~212 (1994)
- Rix M, "Pegvisomant therapy in pituitary gigantism: successful treatment in a 12-year-old girl", Eur J Endocrinol, 153, pp.195~201 (2005)
- Greulich WW, "Radiographic skeletal development of the hand and wrist" (1959), Stanford University Press
- Pandey P, "Pediatric pituitary adenoma: a series of 42 patients", J Clin Neurosci, 12, pp.124~127 (2005)
- Gelber SJ, "Pituitary gigantism caused by growth hormone excess from infancy", J Pediatr, 120, pp.931~934 (1992)
- 김화영, "소아 청소년기에 발생한 뇌하수체 선종 24 증례의 임상상과 치료경과", Annals of Pediatirc Endocrinology & Metabolism, 17(2), pp.82~91 (2012), 대한소아내분비학회[DOI]
- Kim EY, "Pituitary adenomas in childhood and adolescence", J Korean Neurosurg Soc, 24, pp.864~875 (1995)
- Melmed S, "Medical progress: acromegaly", N Engl J Med, 355, pp.2558~2573 (2006)
- Sata A, "Growth hormone measurements in the diagnosis and monitoring of acromegaly", Pituitary, 10, pp.165~172 (2007)
- Schoof E, "Five-year follow-up of a 13-year-old boy with a pituitary adenoma causing gigantism: effect of octreotide therapy", Horm Res, 61, pp.184~189 (2004)
- Barrande G, "Hormonal and metabolic effects of radiotherapy in acromegaly: long-term results in 128patients followed in a single center", J Clin Endocrinol Metab, 85, pp.3779~3785 (2000)
- Ayuk J, "Efficacy of Sandostatin LAR (long-acting somatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and", or radiotherapy, 2004, pp.60, 375~381
- Bevan JS, "Primary medical therapy for acromegaly:an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size", J Clin Endocrinol Metab, 87, pp.4554~4563 (2002)